Notice |
How to write your comments onto a webpage
[2]
| 2016.07.06 | 운영자 | 2016.11.20 | 18167 |
Notice |
How to Upload Pictures in webpages
| 2016.07.06 | 운영자 | 2018.10.19 | 32309 |
Notice |
How to use Rich Text Editor
[3]
| 2016.06.28 | 운영자 | 2018.10.19 | 5891 |
Notice |
How to Write a Webpage
| 2016.06.28 | 운영자 | 2020.12.23 | 43813 |
542 |
환골탈태; 국민의 힘 34세 이준석 당대표 당선
[2] | 2021.06.11 | 온기철*71 | 2021.06.11 | 52 |
541 |
‘영재 신궁’ 고2 김제덕, 올림픽 티켓 명중
[3] | 2021.04.24 | 황규정*65 | 2021.04.24 | 52 |
540 |
북한: 바이든의 전략적 인내
| 2021.02.26 | 온기철*71 | 2021.02.28 | 52 |
539 |
백두산-개마고원-장진호-흥남; 삼수갑산
[5] | 2021.02.06 | 온기철*71 | 2021.02.07 | 52 |
538 |
[Medical] Danger of Endurance Exercise in Elderly
[2] | 2020.06.09 | 이한중*65 | 2020.06.09 | 52 |
537 |
Corona Korea making Vaccine
| 2020.05.05 | 온기철*71 | 2020.05.05 | 52 |
536 |
[Medical] Ace Inhibitors & ARBs Appear Safe in COVID19
[2] | 2020.05.02 | 이한중*65 | 2020.05.02 | 52 |
535 |
Corona Korea; Global Standard, How?
[1] | 2020.04.09 | 온기철*71 | 2020.04.09 | 52 |
534 |
It's Official: Wear Face Mask. CDC
[2] | 2020.04.04 | 이한중*65 | 2020.04.07 | 52 |
533 |
Is this the end of Euro-American dominance?
[3] | 2020.04.02 | 온기철*71 | 2020.04.04 | 52 |
532 |
Coronavirus Dashboard
[1] | 2020.03.20 | 이한중*65 | 2020.03.20 | 52 |
531 |
박인비, 골프위크 선정 최근 '10년간 최고 여자 선수'로 뽑혀
[2] | 2019.11.30 | 황규정*65 | 2019.12.06 | 52 |
530 |
중국 스파이 대만 선거개입
| 2019.11.27 | 온기철*71 | 2019.11.27 | 52 |
529 |
사카모토 료마 46, 47, 48
| 2019.09.22 | 온기철*71 | 2019.09.22 | 52 |
528 |
사카모토 료마; 15,16,17
| 2019.08.31 | 온기철*71 | 2019.08.31 | 52 |
527 |
[PGA] 돌아온 배상문, ‘영건’들과 함께 남자골프 중흥기 열까
[1] | 2017.08.15 | 황규정*65 | 2017.08.15 | 52 |
526 |
김연아 끝내 못넘은 아사다 마오, 비운의 은퇴
[2] | 2017.04.11 | 황규정*65 | 2017.04.12 | 52 |
525 |
[LPGA] 호주교포 이민지, LPGA 투어 ‘블루베이’ 우승2승 수확
[6] | 2016.10.22 | 황규정*65 | 2016.10.24 | 52 |
524 |
리우 올림픽 여자골프 금메달 박인비, 대한민국체육상 수상
[2] | 2016.10.14 | 황규정*65 | 2016.10.16 | 52 |
523 |
Olympic Spirit
[3] | 2016.08.08 | 황규정*65 | 2016.08.09 | 52 |
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
List of authors.
Abstract
BACKGROUND
Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.
METHODS
We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018–2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase–polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed.
RESULTS
A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out.
CONCLUSIONS
Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.)(NEJM July 8, 2020)